Last reviewed · How we verify

Jincaopian Tablets

Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3 active Small molecule

Jincaopian Tablets is a traditional Chinese medicine formulation that modulates immune function and inflammatory pathways to treat respiratory and immune-related conditions.

Jincaopian Tablets is a traditional Chinese medicine formulation that modulates immune function and inflammatory pathways to treat respiratory and immune-related conditions. Used for Respiratory conditions and immune support (specific indication under Phase 3 evaluation).

At a glance

Generic nameJincaopian Tablets
Also known asZY5301
SponsorBeijing Konruns Pharmaceutical Co., Ltd.
ModalitySmall molecule
Therapeutic areaImmunology / Respiratory
PhasePhase 3

Mechanism of action

The tablet formulation combines herbal components traditionally used in Chinese medicine to support respiratory health and immune function. While the exact molecular targets are not well-characterized in Western pharmacological literature, the preparation is believed to work through multiple pathways including anti-inflammatory and immunomodulatory effects. The specific active constituents and their mechanisms require further clinical characterization.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: